Product Images Oxycodone Hcl

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Oxycodone Hcl NDC 55700-791 by Quality Care Products, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image description - New Doc 2019 09 10 13.46.10 1

This is a description of a medication called "Oxycodone Hydrochloride" that comes in a white, round tablet form with “OP 10” imprinted on it, and is packaged in a bottle of 30 tablets. The medication is produced by Purdue Pharmaceuticals and is distributed by KVK-Tech. The medication is potentially habit-forming and should be stored at temperatures between 59-86 degrees F. The instructions for use and any associated warnings can be found in the manufacturer's insert, and it is recommended to consult a physician before taking this medication. Contact information for Purdue Pharmaceuticals and KVK-Tech is also included.*

Table 1 - fig 1 table 1

Table 1 presents conversion factors for switching pediatric patients 11 years and older to Oxycodone HCI Extended-Release Tablets from prior opioids such as Oral and Parenteral types like Oxycodone, Hydrocodone, Hydromorphone, Morphine, and Tramadol. It also includes a note indicating that a more conservative conversion is required for patients receiving high-dose parenteral opioids.*

Table 2 - fig 2 table 2

The table shows common adverse reactions for extended-release oxycodone HCI tablets vs. placebo, based on a sample size of 227. The most common adverse reactions (>5%) are constipation, nausea, somnolence, dizziness, pruritus, vomiting, headache, dry mouth, asthenia, and sweating.*

Table 3 - fig 3 table 3

This is a table showing the incidence of adverse reactions reported in patients aged 11 to 16 years. The table displays the number of patients in the study (140) and the preferred terms for adverse events that were reported by 5% or more of the patients. The most common adverse event was gastrointestinal disorders, reported by 40% of patients. Within this category, vomiting was the most frequent adverse event reported by 21% of patients, followed by nausea, constipation, and diarrhea. Other commonly reported adverse events included nervous system disorders (26%) and general disorders and administration site conditions (23%). Pruritus, a type of skin and subcutaneous tissue disorder, was reported by 16% of patients.*

Table 5 - fig 4 table 5

The table presents data on the maximum drug liking (Epa) after intranasal administration for Oxycodone HCI original extended-release tablets and Finely crushed Oxycodone HCI powdered. The values are measured on the VAS scale where 0 represents maximum negative response, 50 represents neutral response, and 100 represents maximum positive response. Median and Mean values are used to indicate the maximum drug liking and percentage for each drug. The data shows that Oxycodone HCI extended-release tablets have the lowest maximum drug liking values while finely crushed Oxycodone HCI powdered has the highest maximum drug liking values.*

Figure 1 - fig 5 figure 1

Structural Formula - fig 6 chemical structure

Table 6 - fig 7 table 6

This is a table showing the mean [% coefficient of variation] for the Auc, Cmax, and Tinax values for different dosages (10mg, 20mg, and 40mg) of a particular drug under a single-dose regimen form. It is mentioned that the data obtained while subjects received naltrexone (which can enhance absorption). No other information is given.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.